Cinven saw the opportunity to expand into a new field, with Mercury specialising in niche pharmaceuticals, with customers including many hospitals and pharmacies across the UK, as well as a large international market. This niche brand of pharmaceuticals is often protected from patent issues and so was another attractive prospect for Cinven in this deal.
Cinven partner, Supraj Rajagopalan believes this deal “is a fantastic platform for further consolidation in both the UK and internationally” before adding that the investment “demonstrates [Cinven’s] focus on acquiring European based companies with significant international growth prospects.”
John Beighton, CEO of Mercury Pharma, is “delighted to be partnering Cinven who … will provide invaluable expertise and investment.”
Are you looking for a new role in the pharmaceutical industry? Click here to search pharma industry jobs